GPCR Stock Analysis: Buy, Sell, or Hold?
GPCR - Structure Therapeutics Inc. American Depositary Shares
$44.13
-1.79 (-3.90%)
▼
5d:
-10.05%
30d:
-29.93%
90d:
-35.43%
WAIT
LOW Confidence
Analysis Updated: Mar 27, 2026 12:00 AM ET
Earnings: May 14, 2026
Get Alerted When GPCR Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
⏸️ WAIT FOR STABILIZATION: GPCR is down 10.0% over the last 5 days. While fundamentals may be solid, catching a falling knife is risky. Wait for price to stabilize before entering.
⏸️ WAIT FOR STABILIZATION: GPCR is down 10.0% over the last 5 days. While fundamentals may be solid, catching a falling knife is risky. Wait for price to stabilize before entering.
In-depth Analysis How we analyze
Valuation Analysis: GPCR is currently trading at $44.13, which is considered oversold relative to its 30-day fair value range of $54.14 to $67.86.
Technical Outlook: Technically, GPCR is in a uptrend. The price is currently testing key support at $44.77. A bounce from this level would confirm strength, while a break below could signal further downside. Short-term momentum is weak, with the stock down 3.9% recently.
Market Sentiment: The stock shows a mixed technical setup (40/100), with neutral trendline and momentum signals. Wall Street analysts see significant upside, with an average price target of $109.00 (+137.4%). Current signals suggest waiting for a better entry point before initiating new positions.
Technical Outlook: Technically, GPCR is in a uptrend. The price is currently testing key support at $44.77. A bounce from this level would confirm strength, while a break below could signal further downside. Short-term momentum is weak, with the stock down 3.9% recently.
Market Sentiment: The stock shows a mixed technical setup (40/100), with neutral trendline and momentum signals. Wall Street analysts see significant upside, with an average price target of $109.00 (+137.4%). Current signals suggest waiting for a better entry point before initiating new positions.
Quick Decision Summary
Current Position
OVERSOLD
Fair Price Range
$54.14 -
$67.86
Company Quality Score
51/100
(HOLD)
Volume Confirmation
HIGH
Confidence Score
77.4%
All Signals
- BULLISH: Price oversold vs 30-day range
- NEUTRAL: Mixed technical signals (40/100)
- BULLISH: High volume confirmation
- BEARISH: Downward momentum (-3.9%)
- BULLISH: Trading 137.4% below Wall St target ($109.00)
- WARNING: Recommendation downgraded due to -10.0% 5-day decline - wait for stabilization
Fair Price Analysis
30-Day Fair Range
$54.14 -
$67.86
Current vs Fair Value
OVERSOLD
Support & Resistance Levels
Support Level
$44.77
Resistance Level
$61.20
Current Trend
Uptrend
Technical data as of
Mar 27, 2026
Fundamental Context
Forward P/E (Next Year Est.)
-21.27
Wall Street Target
$109.00
(+137.4%)
Share & Embed Analysis
Last updated: March 30, 2026 10:24 AM ET
Data refreshes hourly during market hours. Next update: 11:24 AM
Data refreshes hourly during market hours. Next update: 11:24 AM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is GPCR showing a specific setup today?
Top Rated Biotechnology Stocks
Top-rated stocks in Biotechnology by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
NTLA
Intellia Therapeutics Inc |
STRONG BUY
29 analysts |
$25 | 56 HOLD |
|
ONC
BeiGene, Ltd. |
STRONG BUY
24 analysts |
$411 | 47 HOLD |
|
ACLX
Arcellx Inc |
STRONG BUY
18 analysts |
$111 | 57 HOLD |
|
RCKT
Rocket Pharmaceuticals I… |
STRONG BUY
18 analysts |
$8 | 49 HOLD |
|
APLS
Apellis Pharmaceuticals … |
BUY
22 analysts |
$33 | 53 HOLD |
